ClinicalTrials.Veeva

Menu

Efficacy of Immunomudulatory Therapy With All-trans Retinoid Acid for Adults With Chronic Immune Thrombocytopenia (ITP)

S

Soochow University

Status

Completed

Conditions

Immune Thrombocytopenic Purpura

Treatments

Drug: all-trans-retinoid acid

Study type

Observational

Funder types

Other

Identifiers

NCT01668615
jsxys-123

Details and patient eligibility

About

The purpose of this study is to determine whether All-trans retinoic acid (ATRA) are effective in the treatment of refractory idiopathic thrombocytopenic purpura (RITP).

Full description

Idiopathic thrombocytopenic purpura(ITP), an acquired immune disease is characterized by impaired generation of autoantibody-specific platelet. At least 30% adult patients turn into refractory ITP. The pathogenesis of ITP remains to be elucidated. Now ,CD4+ helper cells have been classified as belong to T-helper 1(TH1), T-helper 2(TH2), T-helper17and Regulory T cell(Tregs). All-trans retinoic acid(ATRA) mainly applied in skin disease and acute promyelocytic leukemia. Recently, ATRA is also a immunomodulator which can induce differentiation, proliferation, apoptosis of cells, and immunomudulatory. In the international, the investigators first treat RITP with ATRA. To investigate the therapeutic effects of ATRA on RITP, and using new index in the cells, cytokines and molecular biology of three in-depth study of its mechanism.

Enrollment

35 patients

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Clinical diagnosis of refratory idiopathic thrombocytopenic purpura
  • Hormone and immune suppression, splenectomy is invalid

Exclusion criteria

  • Other autoimmune diseases

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems